Caris Life Sciences, Inc. (CAI) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$27.50

From 52W high−27.97%

Volume7.80M

Market cap$7.36B

P/E (TTM)77.5x

P/S (TTM)7.0x

Div yield—

Key dataNov 5, 2026

Open

$27.50

From 52W high

−27.97%

Volume

7.80M

Market cap

$7.36B

ValuationView details →

P/E (Fwd)

84.5x

EV/EBITDA

44.1x

P/E (TTM)

77.5x

RSI (14)

38.0

MomentumView details →

1D Return

−21.64%

YTD Return

−0.02%

ValuationView details →

P/E (Fwd)

84.5x

P/E (TTM)

77.5x

EV/EBITDA

44.1x

EV/Sales

6.3x

P/S (TTM)

7.0x

P/B (TTM)

11.5x

ProfitabilityView details →

Gross Margin

51.70%

Net Margin

9.16%

EBITDA Margin

14.24%

ROE (TTM)

15.02%

ROA (TTM)

7.65%

Asset Turnover

0.84x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+46.46%

EPS CAGR 3Y

+29.26%

EBITDA YoY

—

MomentumView details →

1D Return

−21.64%

YTD Return

−0.02%

1Y Return

+9.61%

RSI (14)

38.0

vs 50D SMA

−8.62%

vs 200D SMA

+24.46%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.71x

Quick Ratio

6.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.05

EPS Surprise

77.68%

Beats (12Q)

3/12

Next Q EPS Est

$0.10

Avg Surprise (4Q)

−597.24%

Rev Surprise

7.83%

Financials snapshotView financials →

Revenue (TTM)

1.05B

Net Income (TTM)

96.06M

Op. CF (TTM)

83.89M

Next earningsFeb 25, 2027 →

Latest newsMore news →

Caris Life Sciences reported quarterly earnings of $0.05 per share, compared with $0.08 per share a year earlier.1d ago

Caris Life Sciences raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, representing projected growth of 28%–29%.1d ago

Similar companies

Abivax S.A.ABVX Praxis Precision Medicines, Inc.PRAX 苑东生物688513.SH Rhythm Pharmaceuticals, Inc.RYTM Duality Biotherapeutics, Inc.09606.HK Alkermes plcALKS Find similar companies →

Latest newsMore news →

Caris Life Sciences reported quarterly earnings of $0.05 per share, compared with $0.08 per share a year earlier.1d ago Caris Life Sciences raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, representing projected growth of 28%–29%.1d ago Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, and approximately 61,500 clinical cases comprising more than 358,000 oncology tests.1d ago